{"ticker": {"uuid": "bacb0004-1617-4431-891e-318f192dc23f", "symbol": "CABA", "name": "Cabaletta Bio Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of \"Moderate Buy\" by Analysts", "summary": "Cabaletta Bio, Inc. (NASDAQ:CABA) has received an average analyst rating of \"Moderate Buy\" from seven firms, with an average 1-year price target of $15.50. Recent analyst actions were mixed, including Guggenheim raising its target to $16 and Morgan Stanley cutting its target to $", "url": "https://www.marketbeat.com/instant-alerts/cabaletta-bio-inc-nasdaqcaba-given-average-rating-of-moderate-buy-by-analysts-2026-07-22/", "source_name": "MarketBeat", "published_at": "2026-07-22T06:10:32", "published_display": "22 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio (CABA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary", "summary": "Cabaletta Bio (CABA) provided a summary of its Guggenheim Securities Emerging Outlook: Biotech Summit 2026 presentation, highlighting strategic program updates including pivotal myositis study enrollment, automated manufacturing for rese-cel, and upcoming Phase 1/2 data for autoi", "url": "https://quartr.com/events/cabaletta-bio-caba-guggenheim-securities-emerging-outlook-biotech-summit-2026_Fe5wCWMD", "source_name": "Quartr", "published_at": "2026-07-20T01:12:01", "published_display": "20 Jul 2026 01:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Cabaletta Bio, Inc. Stocks", "summary": "This article lists various ETFs that include Cabaletta Bio, Inc. (CABA) stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of CABA stock, issuer, management style, expense ratio, AUM, price, and performance metrics. The", "url": "https://www.tradingview.com/symbols/BOATS-CABA/etfs/", "source_name": "TradingView", "published_at": "2026-07-17T10:10:07", "published_display": "17 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cabaletta Bio : CABA", "summary": "Cabaletta Bio Inc (CABA) is a biotech company focused on developing engineered T cell therapies for autoimmune diseases, particularly B cell-mediated conditions. Its lead project, DSG3-CAART, is in Phase I trials for mucosal pemphigus vulgaris, and the company is also exploring t", "url": "https://247wallst.com/companies/caba/", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T20:09:33", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cabaletta Bio, Inc. \u2013 NASDAQ:CABA", "summary": "This article provides", "url": "https://www.tradingview.com/symbols/NASDAQ-CABA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T04:40:05", "published_display": "10 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Cabaletta Bio, Inc. \u2013 NASDAQ:CABA", "summary": "The article provides financial information for Cabaletta Bio, Inc. (NASDAQ: CABA), specifically focusing on its enterprise value to EBIT forward. It indicates that the market was closed at the time of the data display and that there were no trades. The period value and change per", "url": "https://www.tradingview.com/symbols/NASDAQ-CABA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T12:39:48", "published_display": "07 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cabaletta Bio, Inc. \u2013 NASDAQ:CABA", "summary": "The article focuses on the \"Price to sales forward\" metric for Cabaletta Bio, Inc. (NASDAQ: CABA). It appears to be a financial data snippet from TradingView, providing an overview of the company's financials for investors and analysts. However, no specific numerical data is pres", "url": "https://www.tradingview.com/symbols/NASDAQ-CABA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T12:10:30", "published_display": "06 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cabaletta Bio, Inc. \u2013 NASDAQ:CABA", "summary": "The article focuses on the \"Price to book forward\" financial metric for Cabaletta Bio, Inc. (NASDAQ: CABA). It presents a specific value for this metric and indicates whether it has changed. The content appears to be a snapshot from a financial data platform like TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-CABA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T11:39:27", "published_display": "05 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Common Stock of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 4-JUL-2026.", "summary": "Certain common stock of Cabaletta Bio, Inc. are subject to a lock-up agreement that ends on July 4, 2026. These shares will be under lockup for 61 days, starting from May 4, 2026. The lock-up agreement prevents executive officers and directors from selling or otherwise disposing ", "url": "https://www.marketscreener.com/news/certain-common-stock-of-cabaletta-bio-inc-are-subject-to-a-lock-up-agreement-ending-on-4-jul-2026-ce7f5edadd89f321", "source_name": "www.marketscreener.com", "published_at": "2026-07-04T23:39:27", "published_display": "04 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio(CABA) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Moomoo", "published_at": "2026-06-30T13:15:03+00:00", "published_display": "30 Jun 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio, Inc.(NasdaqGS:CABA) added to Russell Small Cap Comp Growth Benchmark", "summary": "Cabaletta Bio, Inc. (NasdaqGS:CABA) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is part of several recent additions to Russell Indices, signaling increased visibility and potential liquidity for the biotechnology company. Cabaletta Bio is a clini", "url": "https://www.marketscreener.com/news/cabaletta-bio-inc-nasdaqgs-caba-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc88f426", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T17:08:00", "published_display": "29 Jun 2026 17:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Value Benchmark", "summary": "Cabaletta Bio, Inc. (NasdaqGS: CABA) has been added to the Russell 2000 Value Benchmark. This integration follows similar inclusions in other Russell indices, highlighting the company's growing presence in the market. Cabaletta Bio is a clinical-stage biotechnology company focuse", "url": "https://www.marketscreener.com/news/cabaletta-bio-inc-nasdaqgs-caba-added-to-russell-2000-value-benchmark-ce7f5fdfd88aff22", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:09:57", "published_display": "29 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Growth Benchmark", "summary": "Cabaletta Bio, Inc. (NasdaqGS: CABA) has been added to the Russell 3000E Growth Benchmark, according to an announcement published on June 29, 2026. This news follows other recent index inclusions, including the Russell 3000 Index and the S&P Biotechnology Select Industry Index. T", "url": "https://www.marketscreener.com/news/cabaletta-bio-inc-nasdaqgs-caba-added-to-russell-3000e-growth-benchmark-ce7f5fdedf89f721", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:25:25", "published_display": "29 Jun 2026 08:25", "sentiment": "positive", "sentiment_pct": 78, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CABA - Cabaletta Bio Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Cabaletta Bio Inc (CABA), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, volatility metrics, insider and institutional ownership, ", "url": "https://finviz.com/stock?t=CABA&ta=0&p=d&ty=ocv&b=1&r=m1&ov=chain_date&e=2026-07-17", "source_name": "Finviz", "published_at": "2026-06-26T09:39:59", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio, Inc. Actuals & Estimates (NASDAQ:CABA)", "summary": "This article provides an overview of Cabaletta Bio, Inc. (NASDAQ: CABA) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts with maximum and minimum price estimates, upcoming earnings report dates, and recent financi", "url": "https://www.tradingview.com/symbols/NASDAQ-CABA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:48", "published_display": "26 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNek1TUk1CS2xKR0FlXzNDekVCWWdfbUMzemVhbEFRcXhrUkNyaTlzTDBubFJlcWQ5dkVlaFJaOVdlM01JNm9lR1JOdnpHNnpxZEVyNmZPYlgxVnEyUnF6ODJnV1VCSGJocjQ2c3E2aW03a3lSanFranNUazd3eURLQXVuSzVOVmhrZmpsemJjUXRaVGhkOVFvTzFhOA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio Inc (CABA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article from TradingKey provides an overview of Cabaletta Bio Inc's (CABA) dividend and stock split history. It indicates that CABA has not distributed any dividends over the past five years and has no recorded stock split events. The page also displays current stock informa", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-caba/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:31", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio Inc (CABA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Cabaletta Bio Inc (CABA), listing major individual shareholders and the proportion of shares they hold. It also breaks down shareholder types by category (e.g., Hedge Fund, Investment Advisor) and provides institutional shareholdi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-caba/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T19:40:31", "published_display": "17 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup", "summary": "Cabaletta Bio (NASDAQ:CABA) is making progress with its experimental cell therapy, rese-cel, for autoimmune diseases. The company expects to file for FDA approval in myositis by 2027 and will release more clinical data for pemphigus vulgaris and lupus studies in the second half o", "url": "https://www.insidermonkey.com/blog/how-cabaletta-bio-caba-is-turning-rese-cel-enrollment-and-new-financing-into-a-clearer-autoimmune-cell-therapy-setup-1783026/", "source_name": "Insider Monkey", "published_at": "2026-06-17T15:22:56", "published_display": "17 Jun 2026 15:22", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CABA Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for Cabaletta Bio Inc (CABA), indicating a \"Neutral\" overall technical sentiment based on a combination of moving averages and oscillators. It details momentum indicators like RSI and MACD, key support and resist", "url": "https://intellectia.ai/en/stock/CABA/technical", "source_name": "Intellectia AI", "published_at": "2026-06-17T07:39:56", "published_display": "17 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CABA - Cabaletta Bio Inc Stock Price and Quote", "summary": "This article provides a detailed financial overview and recent news for Cabaletta Bio Inc. (CABA). It includes stock performance metrics, analyst ratings, insider transaction data, and a comprehensive list of press releases and announcements related to their clinical trials and f", "url": "https://finviz.com/stock?t=CABA", "source_name": "Finviz", "published_at": "2026-06-13T03:09:17", "published_display": "13 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22", "summary": "Cabaletta Bio (CABA) director Richard C. Henriques Jr. was granted stock options for 22,000 shares at an exercise price of $3.22 per share. These options expire on June 8, 2036, and will vest in full on the earlier of June 9, 2027, or the date of the company's next annual stockho", "url": "https://www.stocktitan.net/sec-filings/CABA/form-4-cabaletta-bio-inc-insider-trading-activity-b1696957f002.html", "source_name": "Stock Titan", "published_at": "2026-06-11T13:39:15", "published_display": "11 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares", "summary": "Cabaletta Bio stockholders approved an amendment to the company's charter to increase authorized common shares from 300,000,000 to 600,000,000 at their annual meeting on June 9, 2026. This change expands the company's capacity to issue new equity in the future. Additionally, stoc", "url": "https://www.stocktitan.net/sec-filings/CABA/8-k-cabaletta-bio-inc-reports-material-event-fc42756e48a8.html", "source_name": "Stock Titan", "published_at": "2026-06-11T11:09:33", "published_display": "11 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options", "summary": "Cabaletta Bio director Simon Mark received a grant of 22,000 stock options as part of his compensation package. These options have an exercise price of $3.22 per share, expire on June 8, 2036, and will vest in full by June 9, 2027, or the company's next annual stockholder meeting", "url": "https://www.stocktitan.net/sec-filings/CABA/form-4-cabaletta-bio-inc-insider-trading-activity-fa7a6b33897e.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:08:50", "published_display": "10 Jun 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "22,000 options granted to Cabaletta Bio (CABA) director Brun", "summary": "Cabaletta Bio (CABA) director Scott C. Brun was granted 22,000 stock options with an exercise price of $3.22 per share, expiring on June 8, 2036. These compensation-related options vest fully on the earlier of June 9, 2027, or the date of the next annual stockholder meeting. Foll", "url": "https://www.stocktitan.net/sec-filings/CABA/form-4-cabaletta-bio-inc-insider-trading-activity-da5bb15fefc1.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:08:50", "published_display": "10 Jun 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Cabaletta Bio, Inc. Insider Trading Activity", "summary": "Cabaletta Bio, Inc. director Shawn Tomasello was granted stock options for 22,000 shares with an exercise price of $3.22. This grant is a compensation-related award, not an open-market transaction, and vests fully by June 9, 2027, or the next annual meeting. Following this, Tomas", "url": "https://www.stocktitan.net/sec-filings/CABA/form-4-cabaletta-bio-inc-insider-trading-activity-198c54e1ea00.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:08:50", "published_display": "10 Jun 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CABA: Rese-cel delivers durable, safe remissions in myositis, supporting rapid outpatient adoption", "summary": "Cabaletta Bio's Rese-cel shows durable, immunomodulator-free remissions and strong safety in myositis patients, allowing for outpatient dosing and quick adoption. The company plans a BLA submission in the second half of 2027, potentially benefiting from a priority review voucher ", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3519824:0-caba-rese-cel-delivers-durable-safe-remissions-in-myositis-supporting-rapid-outpatient-adoption/", "source_name": "TradingView", "published_at": "2026-06-08T16:09:29", "published_display": "08 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases", "summary": "Cabaletta Bio Inc. (CABA) is positioned as a top penny stock, having released positive clinical data for its investigational CAR T cell therapy, rese-cel, for autoimmune diseases. The company is advancing rese-cel towards BLA submission and eventual commercial launch, signing a l", "url": "https://www.insidermonkey.com/blog/cabaletta-bio-inc-caba-a-top-penny-stock-eyeing-rese-cel-commercial-launch-for-autoimmune-diseases-1776516/", "source_name": "Insider Monkey", "published_at": "2026-06-07T13:58:00", "published_display": "07 Jun 2026 13:58", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors\u2019 Stock Portfolio: Top 5 Penny Stocks To Buy", "summary": "This article lists the top 5 penny stocks for investors' portfolios, providing details for Cabaletta Bio Inc. (NASDAQ: CABA) as one example. It highlights the company's positive clinical data from its CAR T cell therapy for autoimmune diseases, production agreements, and future B", "url": "https://www.insidermonkey.com/blog/investors-stock-portfolio-top-5-penny-stocks-to-buy-1775164/", "source_name": "Insider Monkey", "published_at": "2026-06-05T21:00:00", "published_display": "05 Jun 2026 21:00", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQb0ZqREVpM2lKQV9wNm8tdHpTcWxuQWpoakhXNGdnVDdpZFN0bmhjc2FQVkFMdlhVRE5nUkwzNkZFUXpna2ZROVdUbGtkbUpaZmthWHN4dlZqSzRoRlpONDF0WUM0dGtfZVl1ajEtbmNoOW1sTG4tVm9KWFd4dlYxVjNVSThZbTBpdDBmSm1nemVNa1UwTVRvSWxGdkNmdGh0TTQ5RG1ENnliX3JyWlVOX1EzUE5VdUt1ZFdBR0JKQVZDRXljejMtQldrVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio Reports 83% Response Rate for Rese-cel in Dermatomyositis", "summary": "Cabaletta Bio announced an 83% response rate for its drug rese-cel in dermatomyositis patients during the RESET-Myositis trial, with responses maintained for up to 1.5 years. The company plans a 2027 BLA submission for dermatomyositis and is also pursuing systemic sclerosis with ", "url": "https://www.clinicaltrialvanguard.com/news/cabaletta-bio-reports-83-response-rate-for-rese-cel-in-dermatomyositis/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-06-05T06:39:21", "published_display": "05 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio's Rese-cel Shows Potential in Treating Autoimmune Diseases", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cabaletta-bio-apos-rese-cel-123149654.html", "source_name": "MT Newswires", "published_at": "2026-06-03T12:31:49+00:00", "published_display": "03 Jun 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cabaletta-bio-announces-rese-cel-110000904.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T11:00:00+00:00", "published_display": "03 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CABA: Cabaletta Bio Shares Positive Clinical Updates at EULAR 20", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQckxmTVVkT0FhWnFaMjlLLVVJVXdqdmU1Yy16US03TnhXOTYxRjQzM0doQ1l2OVdsa1VHTm9xa1pEYVJzQkNlbHY3RFliYWpLaUg3RzNvSWJPWUhuclZ3ellGdG1obUpFeE9QVl9qQmJpTWVpTDZVQ1hfbUJXRktDWFJKYzR0dndGd29RTzZQRVIyWk9RTGlIbVFRX2Z2YWZZbVVBYlZnd0xRSDROdHI4bnoxZmZ2b3FTUm44ckhfUjBxQUtRZVctXzJMNTNhUU9TMWhFemFhVjVlM3ph?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies reiterates Cabaletta Bio stock rating on autoimmune data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQSDROSnBZRWpIaXBOcmtKaWFnMjlNbE5nVkNLTXV2bTFVeWtYZ2FUa044YVVPQ2U0dkRxLTlMT3Y4N1V3V01nT0ZfUTBCR1plVjBCcmFSaV9kTWs1NC05UDh5VnZMeTdocGpUdVdpWWFEcnlydmJkSlk0Ykl2N2taT0JrVjQxWV9wZ0tBckcxczBlVEwwVWpORHozT0RpelV1a1pNNTE2MVVNdURyUnI1bVQySTN3MllRd3ZkYkhNRkhQZFFs?oc=5", "source_name": "Investing.com", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and Novartis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pemphigus-vulgaris-market-analysis-report-114200151.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T11:42:00+00:00", "published_display": "21 May 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPbllIYm96WExycGpMaXRiSks2bUN4bU9MYmM0azA3ZXRCYzVPd1dwR3pEbUpZM2dySG5jSkpILWtQcXEzYy1ic3JoSXFmalVrcHl4U01PbWNTekpQTllMbnFDUzhBR3pNYXZYa2pkX2lBZm9qRHdoTjJadUUwYmxEVnJLdGNCYW9WTm9tZi1FaGQ0TzdhX3BUQ3ZXMy12eGgw?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio (CABA) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPVlRBS0ZuV0V6Z2FIX1BfTGFKVjJfOV82UU5FSlZ1M2RRbkFJNXJPTGNKQ3lFOTVmTlFzR0JTajFLd0kzenVpOEtQUmdWazN6WlVNY2pFSGdTemtSN0RjdG5EZ290X1EtaWN0ZHI2R01nLVRKM3VuU3dOczRQd2RHeHBqOG1BSFRZRWtJRjgzZ3FEMDduSmo0aVQ1Z0I?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cabaletta Bio (CABA) Is Up 34.2% After Early RESET-PV Data And US$150M Equity Raise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Cabaletta Bio (CABA) Valuation After 10 Year Cellares Supply Deal And Upcoming Rese Cel Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio prices $150 million public offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPM2VXcDhEUTJoci1hSUYwZkMyeHQ2VFB0MlpCUU1VVUNfZ0pTc2VhMFprWVcwUVpQZlhyRi03WUVMQk0wVGRuOUpaV1MyRFAtakMwUWRWWjZXdGFIUG55eEYtSTBERmVrNVlpeGFCMmwxZmFwR1dRbmFta3Y2ZWJEYVFBUDZzRXM3X0QtX1U2bmVtVnoyVzY5Qw?oc=5", "source_name": "The Pharma Letter", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Backed by Eli Lilly, Cabaletta sells $150M in new shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNaWJScGI1VTJTSzA0VUZvYk5FSHFhLXJwYWVSRnBZM295VXBVQ0RWa2hWVjdLQVpnc0lMS0hpVnNvMFE2LXFXaHE5SUlMVE4xTnIxZHVvVkdpN19wVzNzZVk2UzFWamFUZEpnVDhDTkY4d2RDSldTWWFhX0NndVBndGtmX1BGSjNlWVg0VDlEU0RvaVIxWHV6Q0VHeXE2Y29YZlAwVXV1bERibEVzQ2JfcTVXR2g?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOODZqeG9lU1FVU1BwclhjUzJTdXdTZndpYVhhUk93TzRRaGVOOXh4ZjlKNDdSUm9VVWpHd0VNM2l1d2kzZGZ1UnBidVpNSXFQcExYRzZpXzN3MWViY015TVZ0TGtkVXJLR3NkWERkYkZwMzdCVTlxWnVWSklLc25zcFExV2tIakNiaVlZTS11NmU2VHFIRGRQV3AxS2NaTGZ4TnRQM2dBNA?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio, Inc. to Present New Data on Rese-cel at ASGCT 2026 Annual Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQc3VYOTNfY1BYVE8zYmJ5Z3hUMUl1aFVPdUtzYWRLM1V4cklYb21OWGhhS01mYU42YnRpSWRhMDV2aUpoNmFKVXh0M1d0QkZaR3d6RlVYbmwzMWVBejg5Z2liSFIxSmFPYnUzUEpFS0FxNXRxY3R5ZDQ2bU1jcTlGWWxXb0k0RUE0U2lCNmdTV2ZFYlZDRVpweTFfeHBUQWwwS3RWbGRCNVlEN3BWbXF6cG1Nd0pjQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta starts automated cell-therapy manufacturing, targets thousands a year", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdG9xX1ZtMGd6TmZ2ZENyQ2VqVkVzMldYUmtYaE1ZNTMzTnM4MjRKQlNBaGNVS1NScHlmRGY5NFJtTTZMdFZFSzk4cldZQnlDYTJDYU42dEFTeGNSQlhuN3JOeFZfSmlGRjlSNk9ZQzFEYUI0ektXbXJOOTVRcVZoTnF0eTNMWUxOUHFyUlBlb1hWeVB4NHlrbnBsMWpFTG83MnkwQ18wRUtkZk5MVVMxd256U0R2QXpRaTZZSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autoimmune cell therapy group Cabaletta Bio at TD Cowen health conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeVJQMmlYb0ZfZ3lvWGpnTWpQQnI4bXNTTllKSmdJd0xoVlF0VkJTaldDTVlEVDZycnNMU0ZuVHdXWWZMcnZRZjJQTUV2OW1ZTDNIZ05DRjE5d3Q3T1F6Tm9lSXI0Z3ktRDFpaXhOS3lFUUllcTctNnEwX0hBZGZEWlVYTE1IeHFHLUtHQUhfLTExWmZlQnFhdFBsMURkMnRCcUVYWEpxYXU1a0xGNzhlRGZfWmcxeXhEaHlNMTNsZTk?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Jacob Funds Established a Position in Cabaletta Bio (CABA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPWWxMdkdSWHBxMDZGS3BXSjlLVEs1NGtTYWd6QlB4NDJpWGRHcWc3YjE3WHN3c21qNXFXT282UjBtN3A5YXNLamRGbzBNdWdHYVBQRmJ4VFAxemJPSlZadU9QbnpQSTh1OTRzeHpUZWxkVEtKTWJKdlVCVy1RQUFtaFUwblJSSTgwTHc?oc=5", "source_name": "Market source", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBYR2lXZU9KRFZyMlk1cXBmenNwX0pMQXFBQlozMHRjMk4ybE5GQXVqN2V3U1NZZVZJRDdBd3pGX0lDVjdqS3RmQ0YyN29Vbk94ZkpZZFh5UXBHRWlaSTFvQUh0RWxCSUd2T0ExQmZkMEg0cW5RODBPMnNUeVktaU0?oc=5", "source_name": "Market source", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim reiterates Buy rating on Cabaletta Bio stock, citing commercial plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPamFjcGE4SFlHcDVPMDVzODZOZnBLVDRWSVNPVTBXVHRkbjdaRmJhODhhbDFZbk9CUFNnOEdncE5nZ0kzVlAxb21LSmdpR1BFN21OQUszeXdKSTMyTkIyZDk1WTVLSDgyYW5SWjc0Z3hiMlRmRGFVTHR4aFpQdXAwM2d6aXJPUlBobHpOaU0yODRUdnhpYWdyM2ZLcTQxY2tJcVVhRFp1QjJhZE9IcW1QeUI5VWluaEhaV0FINndkVGEzTmZBYXFSS1dwVHVhQWc3aWtycQ?oc=5", "source_name": "Investing.com", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxOdlhYSDhtRXNpeVF6ZEpMWXFneGVjSVFGOWpTaExDbF9tR3cyZ1RFWHBCSWpUSjVfcVRSd0w5Z09CYWx0LUx3S09JS2w2MkpFblM4cWpCQlN4SjJkcmF3ZlVsYXNkQ2luUXhuWlpJRUtPM3NtSU1iUkIyLWU5UFZZZ05KNzFCb2F3eGFvZA?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of \"Moderate Buy\" by Analysts", "summary": "Cabaletta Bio, Inc. (NASDAQ:CABA) has received an average analyst rating of \"Moderate Buy\" from seven firms, with an average 1-year price target of $15.50. Recent analyst actions were mixed, including Guggenheim raising its target to $16 and Morgan Stanley cutting its target to $", "url": "https://www.marketbeat.com/instant-alerts/cabaletta-bio-inc-nasdaqcaba-given-average-rating-of-moderate-buy-by-analysts-2026-07-22/", "source_name": "MarketBeat", "published_at": "2026-07-22T06:10:32", "published_display": "22 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio (CABA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary", "summary": "Cabaletta Bio (CABA) provided a summary of its Guggenheim Securities Emerging Outlook: Biotech Summit 2026 presentation, highlighting strategic program updates including pivotal myositis study enrollment, automated manufacturing for rese-cel, and upcoming Phase 1/2 data for autoi", "url": "https://quartr.com/events/cabaletta-bio-caba-guggenheim-securities-emerging-outlook-biotech-summit-2026_Fe5wCWMD", "source_name": "Quartr", "published_at": "2026-07-20T01:12:01", "published_display": "20 Jul 2026 01:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Cabaletta Bio, Inc. Stocks", "summary": "This article lists various ETFs that include Cabaletta Bio, Inc. (CABA) stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of CABA stock, issuer, management style, expense ratio, AUM, price, and performance metrics. The", "url": "https://www.tradingview.com/symbols/BOATS-CABA/etfs/", "source_name": "TradingView", "published_at": "2026-07-17T10:10:07", "published_display": "17 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio : CABA", "summary": "Cabaletta Bio Inc (CABA) is a biotech company focused on developing engineered T cell therapies for autoimmune diseases, particularly B cell-mediated conditions. Its lead project, DSG3-CAART, is in Phase I trials for mucosal pemphigus vulgaris, and the company is also exploring t", "url": "https://247wallst.com/companies/caba/", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T20:09:33", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cabaletta Bio, Inc. \u2013 NASDAQ:CABA", "summary": "This article provides", "url": "https://www.tradingview.com/symbols/NASDAQ-CABA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T04:40:05", "published_display": "10 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Cabaletta Bio, Inc. \u2013 NASDAQ:CABA", "summary": "The article provides financial information for Cabaletta Bio, Inc. (NASDAQ: CABA), specifically focusing on its enterprise value to EBIT forward. It indicates that the market was closed at the time of the data display and that there were no trades. The period value and change per", "url": "https://www.tradingview.com/symbols/NASDAQ-CABA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T12:39:48", "published_display": "07 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cabaletta Bio, Inc. \u2013 NASDAQ:CABA", "summary": "The article focuses on the \"Price to sales forward\" metric for Cabaletta Bio, Inc. (NASDAQ: CABA). It appears to be a financial data snippet from TradingView, providing an overview of the company's financials for investors and analysts. However, no specific numerical data is pres", "url": "https://www.tradingview.com/symbols/NASDAQ-CABA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T12:10:30", "published_display": "06 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cabaletta Bio, Inc. \u2013 NASDAQ:CABA", "summary": "The article focuses on the \"Price to book forward\" financial metric for Cabaletta Bio, Inc. (NASDAQ: CABA). It presents a specific value for this metric and indicates whether it has changed. The content appears to be a snapshot from a financial data platform like TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-CABA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T11:39:27", "published_display": "05 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Common Stock of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 4-JUL-2026.", "summary": "Certain common stock of Cabaletta Bio, Inc. are subject to a lock-up agreement that ends on July 4, 2026. These shares will be under lockup for 61 days, starting from May 4, 2026. The lock-up agreement prevents executive officers and directors from selling or otherwise disposing ", "url": "https://www.marketscreener.com/news/certain-common-stock-of-cabaletta-bio-inc-are-subject-to-a-lock-up-agreement-ending-on-4-jul-2026-ce7f5edadd89f321", "source_name": "www.marketscreener.com", "published_at": "2026-07-04T23:39:27", "published_display": "04 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio(CABA) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Moomoo", "published_at": "2026-06-30T13:15:03+00:00", "published_display": "30 Jun 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio, Inc.(NasdaqGS:CABA) added to Russell Small Cap Comp Growth Benchmark", "summary": "Cabaletta Bio, Inc. (NasdaqGS:CABA) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is part of several recent additions to Russell Indices, signaling increased visibility and potential liquidity for the biotechnology company. Cabaletta Bio is a clini", "url": "https://www.marketscreener.com/news/cabaletta-bio-inc-nasdaqgs-caba-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc88f426", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T17:08:00", "published_display": "29 Jun 2026 17:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Value Benchmark", "summary": "Cabaletta Bio, Inc. (NasdaqGS: CABA) has been added to the Russell 2000 Value Benchmark. This integration follows similar inclusions in other Russell indices, highlighting the company's growing presence in the market. Cabaletta Bio is a clinical-stage biotechnology company focuse", "url": "https://www.marketscreener.com/news/cabaletta-bio-inc-nasdaqgs-caba-added-to-russell-2000-value-benchmark-ce7f5fdfd88aff22", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:09:57", "published_display": "29 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Growth Benchmark", "summary": "Cabaletta Bio, Inc. (NasdaqGS: CABA) has been added to the Russell 3000E Growth Benchmark, according to an announcement published on June 29, 2026. This news follows other recent index inclusions, including the Russell 3000 Index and the S&P Biotechnology Select Industry Index. T", "url": "https://www.marketscreener.com/news/cabaletta-bio-inc-nasdaqgs-caba-added-to-russell-3000e-growth-benchmark-ce7f5fdedf89f721", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:25:25", "published_display": "29 Jun 2026 08:25", "sentiment": "positive", "sentiment_pct": 78, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CABA - Cabaletta Bio Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Cabaletta Bio Inc (CABA), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, volatility metrics, insider and institutional ownership, ", "url": "https://finviz.com/stock?t=CABA&ta=0&p=d&ty=ocv&b=1&r=m1&ov=chain_date&e=2026-07-17", "source_name": "Finviz", "published_at": "2026-06-26T09:39:59", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio, Inc. Actuals & Estimates (NASDAQ:CABA)", "summary": "This article provides an overview of Cabaletta Bio, Inc. (NASDAQ: CABA) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts with maximum and minimum price estimates, upcoming earnings report dates, and recent financi", "url": "https://www.tradingview.com/symbols/NASDAQ-CABA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:48", "published_display": "26 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNek1TUk1CS2xKR0FlXzNDekVCWWdfbUMzemVhbEFRcXhrUkNyaTlzTDBubFJlcWQ5dkVlaFJaOVdlM01JNm9lR1JOdnpHNnpxZEVyNmZPYlgxVnEyUnF6ODJnV1VCSGJocjQ2c3E2aW03a3lSanFranNUazd3eURLQXVuSzVOVmhrZmpsemJjUXRaVGhkOVFvTzFhOA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio Inc (CABA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article from TradingKey provides an overview of Cabaletta Bio Inc's (CABA) dividend and stock split history. It indicates that CABA has not distributed any dividends over the past five years and has no recorded stock split events. The page also displays current stock informa", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-caba/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:31", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio Inc (CABA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Cabaletta Bio Inc (CABA), listing major individual shareholders and the proportion of shares they hold. It also breaks down shareholder types by category (e.g., Hedge Fund, Investment Advisor) and provides institutional shareholdi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-caba/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T19:40:31", "published_display": "17 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup", "summary": "Cabaletta Bio (NASDAQ:CABA) is making progress with its experimental cell therapy, rese-cel, for autoimmune diseases. The company expects to file for FDA approval in myositis by 2027 and will release more clinical data for pemphigus vulgaris and lupus studies in the second half o", "url": "https://www.insidermonkey.com/blog/how-cabaletta-bio-caba-is-turning-rese-cel-enrollment-and-new-financing-into-a-clearer-autoimmune-cell-therapy-setup-1783026/", "source_name": "Insider Monkey", "published_at": "2026-06-17T15:22:56", "published_display": "17 Jun 2026 15:22", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CABA Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for Cabaletta Bio Inc (CABA), indicating a \"Neutral\" overall technical sentiment based on a combination of moving averages and oscillators. It details momentum indicators like RSI and MACD, key support and resist", "url": "https://intellectia.ai/en/stock/CABA/technical", "source_name": "Intellectia AI", "published_at": "2026-06-17T07:39:56", "published_display": "17 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CABA - Cabaletta Bio Inc Stock Price and Quote", "summary": "This article provides a detailed financial overview and recent news for Cabaletta Bio Inc. (CABA). It includes stock performance metrics, analyst ratings, insider transaction data, and a comprehensive list of press releases and announcements related to their clinical trials and f", "url": "https://finviz.com/stock?t=CABA", "source_name": "Finviz", "published_at": "2026-06-13T03:09:17", "published_display": "13 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22", "summary": "Cabaletta Bio (CABA) director Richard C. Henriques Jr. was granted stock options for 22,000 shares at an exercise price of $3.22 per share. These options expire on June 8, 2036, and will vest in full on the earlier of June 9, 2027, or the date of the company's next annual stockho", "url": "https://www.stocktitan.net/sec-filings/CABA/form-4-cabaletta-bio-inc-insider-trading-activity-b1696957f002.html", "source_name": "Stock Titan", "published_at": "2026-06-11T13:39:15", "published_display": "11 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares", "summary": "Cabaletta Bio stockholders approved an amendment to the company's charter to increase authorized common shares from 300,000,000 to 600,000,000 at their annual meeting on June 9, 2026. This change expands the company's capacity to issue new equity in the future. Additionally, stoc", "url": "https://www.stocktitan.net/sec-filings/CABA/8-k-cabaletta-bio-inc-reports-material-event-fc42756e48a8.html", "source_name": "Stock Titan", "published_at": "2026-06-11T11:09:33", "published_display": "11 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options", "summary": "Cabaletta Bio director Simon Mark received a grant of 22,000 stock options as part of his compensation package. These options have an exercise price of $3.22 per share, expire on June 8, 2036, and will vest in full by June 9, 2027, or the company's next annual stockholder meeting", "url": "https://www.stocktitan.net/sec-filings/CABA/form-4-cabaletta-bio-inc-insider-trading-activity-fa7a6b33897e.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:08:50", "published_display": "10 Jun 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "22,000 options granted to Cabaletta Bio (CABA) director Brun", "summary": "Cabaletta Bio (CABA) director Scott C. Brun was granted 22,000 stock options with an exercise price of $3.22 per share, expiring on June 8, 2036. These compensation-related options vest fully on the earlier of June 9, 2027, or the date of the next annual stockholder meeting. Foll", "url": "https://www.stocktitan.net/sec-filings/CABA/form-4-cabaletta-bio-inc-insider-trading-activity-da5bb15fefc1.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:08:50", "published_display": "10 Jun 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Cabaletta Bio, Inc. Insider Trading Activity", "summary": "Cabaletta Bio, Inc. director Shawn Tomasello was granted stock options for 22,000 shares with an exercise price of $3.22. This grant is a compensation-related award, not an open-market transaction, and vests fully by June 9, 2027, or the next annual meeting. Following this, Tomas", "url": "https://www.stocktitan.net/sec-filings/CABA/form-4-cabaletta-bio-inc-insider-trading-activity-198c54e1ea00.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:08:50", "published_display": "10 Jun 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CABA: Rese-cel delivers durable, safe remissions in myositis, supporting rapid outpatient adoption", "summary": "Cabaletta Bio's Rese-cel shows durable, immunomodulator-free remissions and strong safety in myositis patients, allowing for outpatient dosing and quick adoption. The company plans a BLA submission in the second half of 2027, potentially benefiting from a priority review voucher ", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3519824:0-caba-rese-cel-delivers-durable-safe-remissions-in-myositis-supporting-rapid-outpatient-adoption/", "source_name": "TradingView", "published_at": "2026-06-08T16:09:29", "published_display": "08 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases", "summary": "Cabaletta Bio Inc. (CABA) is positioned as a top penny stock, having released positive clinical data for its investigational CAR T cell therapy, rese-cel, for autoimmune diseases. The company is advancing rese-cel towards BLA submission and eventual commercial launch, signing a l", "url": "https://www.insidermonkey.com/blog/cabaletta-bio-inc-caba-a-top-penny-stock-eyeing-rese-cel-commercial-launch-for-autoimmune-diseases-1776516/", "source_name": "Insider Monkey", "published_at": "2026-06-07T13:58:00", "published_display": "07 Jun 2026 13:58", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors\u2019 Stock Portfolio: Top 5 Penny Stocks To Buy", "summary": "This article lists the top 5 penny stocks for investors' portfolios, providing details for Cabaletta Bio Inc. (NASDAQ: CABA) as one example. It highlights the company's positive clinical data from its CAR T cell therapy for autoimmune diseases, production agreements, and future B", "url": "https://www.insidermonkey.com/blog/investors-stock-portfolio-top-5-penny-stocks-to-buy-1775164/", "source_name": "Insider Monkey", "published_at": "2026-06-05T21:00:00", "published_display": "05 Jun 2026 21:00", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQb0ZqREVpM2lKQV9wNm8tdHpTcWxuQWpoakhXNGdnVDdpZFN0bmhjc2FQVkFMdlhVRE5nUkwzNkZFUXpna2ZROVdUbGtkbUpaZmthWHN4dlZqSzRoRlpONDF0WUM0dGtfZVl1ajEtbmNoOW1sTG4tVm9KWFd4dlYxVjNVSThZbTBpdDBmSm1nemVNa1UwTVRvSWxGdkNmdGh0TTQ5RG1ENnliX3JyWlVOX1EzUE5VdUt1ZFdBR0JKQVZDRXljejMtQldrVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio Reports 83% Response Rate for Rese-cel in Dermatomyositis", "summary": "Cabaletta Bio announced an 83% response rate for its drug rese-cel in dermatomyositis patients during the RESET-Myositis trial, with responses maintained for up to 1.5 years. The company plans a 2027 BLA submission for dermatomyositis and is also pursuing systemic sclerosis with ", "url": "https://www.clinicaltrialvanguard.com/news/cabaletta-bio-reports-83-response-rate-for-rese-cel-in-dermatomyositis/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-06-05T06:39:21", "published_display": "05 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio's Rese-cel Shows Potential in Treating Autoimmune Diseases", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cabaletta-bio-apos-rese-cel-123149654.html", "source_name": "MT Newswires", "published_at": "2026-06-03T12:31:49+00:00", "published_display": "03 Jun 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cabaletta-bio-announces-rese-cel-110000904.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T11:00:00+00:00", "published_display": "03 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CABA: Cabaletta Bio Shares Positive Clinical Updates at EULAR 20", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQckxmTVVkT0FhWnFaMjlLLVVJVXdqdmU1Yy16US03TnhXOTYxRjQzM0doQ1l2OVdsa1VHTm9xa1pEYVJzQkNlbHY3RFliYWpLaUg3RzNvSWJPWUhuclZ3ellGdG1obUpFeE9QVl9qQmJpTWVpTDZVQ1hfbUJXRktDWFJKYzR0dndGd29RTzZQRVIyWk9RTGlIbVFRX2Z2YWZZbVVBYlZnd0xRSDROdHI4bnoxZmZ2b3FTUm44ckhfUjBxQUtRZVctXzJMNTNhUU9TMWhFemFhVjVlM3ph?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies reiterates Cabaletta Bio stock rating on autoimmune data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQSDROSnBZRWpIaXBOcmtKaWFnMjlNbE5nVkNLTXV2bTFVeWtYZ2FUa044YVVPQ2U0dkRxLTlMT3Y4N1V3V01nT0ZfUTBCR1plVjBCcmFSaV9kTWs1NC05UDh5VnZMeTdocGpUdVdpWWFEcnlydmJkSlk0Ykl2N2taT0JrVjQxWV9wZ0tBckcxczBlVEwwVWpORHozT0RpelV1a1pNNTE2MVVNdURyUnI1bVQySTN3MllRd3ZkYkhNRkhQZFFs?oc=5", "source_name": "Investing.com", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and Novartis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pemphigus-vulgaris-market-analysis-report-114200151.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T11:42:00+00:00", "published_display": "21 May 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPbllIYm96WExycGpMaXRiSks2bUN4bU9MYmM0azA3ZXRCYzVPd1dwR3pEbUpZM2dySG5jSkpILWtQcXEzYy1ic3JoSXFmalVrcHl4U01PbWNTekpQTllMbnFDUzhBR3pNYXZYa2pkX2lBZm9qRHdoTjJadUUwYmxEVnJLdGNCYW9WTm9tZi1FaGQ0TzdhX3BUQ3ZXMy12eGgw?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio (CABA) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPVlRBS0ZuV0V6Z2FIX1BfTGFKVjJfOV82UU5FSlZ1M2RRbkFJNXJPTGNKQ3lFOTVmTlFzR0JTajFLd0kzenVpOEtQUmdWazN6WlVNY2pFSGdTemtSN0RjdG5EZ290X1EtaWN0ZHI2R01nLVRKM3VuU3dOczRQd2RHeHBqOG1BSFRZRWtJRjgzZ3FEMDduSmo0aVQ1Z0I?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio (CABA) Is Up 34.2% After Early RESET-PV Data And US$150M Equity Raise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Cabaletta Bio (CABA) Valuation After 10 Year Cellares Supply Deal And Upcoming Rese Cel Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio prices $150 million public offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPM2VXcDhEUTJoci1hSUYwZkMyeHQ2VFB0MlpCUU1VVUNfZ0pTc2VhMFprWVcwUVpQZlhyRi03WUVMQk0wVGRuOUpaV1MyRFAtakMwUWRWWjZXdGFIUG55eEYtSTBERmVrNVlpeGFCMmwxZmFwR1dRbmFta3Y2ZWJEYVFBUDZzRXM3X0QtX1U2bmVtVnoyVzY5Qw?oc=5", "source_name": "The Pharma Letter", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Backed by Eli Lilly, Cabaletta sells $150M in new shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNaWJScGI1VTJTSzA0VUZvYk5FSHFhLXJwYWVSRnBZM295VXBVQ0RWa2hWVjdLQVpnc0lMS0hpVnNvMFE2LXFXaHE5SUlMVE4xTnIxZHVvVkdpN19wVzNzZVk2UzFWamFUZEpnVDhDTkY4d2RDSldTWWFhX0NndVBndGtmX1BGSjNlWVg0VDlEU0RvaVIxWHV6Q0VHeXE2Y29YZlAwVXV1bERibEVzQ2JfcTVXR2g?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOODZqeG9lU1FVU1BwclhjUzJTdXdTZndpYVhhUk93TzRRaGVOOXh4ZjlKNDdSUm9VVWpHd0VNM2l1d2kzZGZ1UnBidVpNSXFQcExYRzZpXzN3MWViY015TVZ0TGtkVXJLR3NkWERkYkZwMzdCVTlxWnVWSklLc25zcFExV2tIakNiaVlZTS11NmU2VHFIRGRQV3AxS2NaTGZ4TnRQM2dBNA?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta Bio, Inc. to Present New Data on Rese-cel at ASGCT 2026 Annual Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQc3VYOTNfY1BYVE8zYmJ5Z3hUMUl1aFVPdUtzYWRLM1V4cklYb21OWGhhS01mYU42YnRpSWRhMDV2aUpoNmFKVXh0M1d0QkZaR3d6RlVYbmwzMWVBejg5Z2liSFIxSmFPYnUzUEpFS0FxNXRxY3R5ZDQ2bU1jcTlGWWxXb0k0RUE0U2lCNmdTV2ZFYlZDRVpweTFfeHBUQWwwS3RWbGRCNVlEN3BWbXF6cG1Nd0pjQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cabaletta starts automated cell-therapy manufacturing, targets thousands a year", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdG9xX1ZtMGd6TmZ2ZENyQ2VqVkVzMldYUmtYaE1ZNTMzTnM4MjRKQlNBaGNVS1NScHlmRGY5NFJtTTZMdFZFSzk4cldZQnlDYTJDYU42dEFTeGNSQlhuN3JOeFZfSmlGRjlSNk9ZQzFEYUI0ektXbXJOOTVRcVZoTnF0eTNMWUxOUHFyUlBlb1hWeVB4NHlrbnBsMWpFTG83MnkwQ18wRUtkZk5MVVMxd256U0R2QXpRaTZZSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autoimmune cell therapy group Cabaletta Bio at TD Cowen health conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeVJQMmlYb0ZfZ3lvWGpnTWpQQnI4bXNTTllKSmdJd0xoVlF0VkJTaldDTVlEVDZycnNMU0ZuVHdXWWZMcnZRZjJQTUV2OW1ZTDNIZ05DRjE5d3Q3T1F6Tm9lSXI0Z3ktRDFpaXhOS3lFUUllcTctNnEwX0hBZGZEWlVYTE1IeHFHLUtHQUhfLTExWmZlQnFhdFBsMURkMnRCcUVYWEpxYXU1a0xGNzhlRGZfWmcxeXhEaHlNMTNsZTk?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Jacob Funds Established a Position in Cabaletta Bio (CABA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPWWxMdkdSWHBxMDZGS3BXSjlLVEs1NGtTYWd6QlB4NDJpWGRHcWc3YjE3WHN3c21qNXFXT282UjBtN3A5YXNLamRGbzBNdWdHYVBQRmJ4VFAxemJPSlZadU9QbnpQSTh1OTRzeHpUZWxkVEtKTWJKdlVCVy1RQUFtaFUwblJSSTgwTHc?oc=5", "source_name": "Market source", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBYR2lXZU9KRFZyMlk1cXBmenNwX0pMQXFBQlozMHRjMk4ybE5GQXVqN2V3U1NZZVZJRDdBd3pGX0lDVjdqS3RmQ0YyN29Vbk94ZkpZZFh5UXBHRWlaSTFvQUh0RWxCSUd2T0ExQmZkMEg0cW5RODBPMnNUeVktaU0?oc=5", "source_name": "Market source", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim reiterates Buy rating on Cabaletta Bio stock, citing commercial plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPamFjcGE4SFlHcDVPMDVzODZOZnBLVDRWSVNPVTBXVHRkbjdaRmJhODhhbDFZbk9CUFNnOEdncE5nZ0kzVlAxb21LSmdpR1BFN21OQUszeXdKSTMyTkIyZDk1WTVLSDgyYW5SWjc0Z3hiMlRmRGFVTHR4aFpQdXAwM2d6aXJPUlBobHpOaU0yODRUdnhpYWdyM2ZLcTQxY2tJcVVhRFp1QjJhZE9IcW1QeUI5VWluaEhaV0FINndkVGEzTmZBYXFSS1dwVHVhQWc3aWtycQ?oc=5", "source_name": "Investing.com", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxOdlhYSDhtRXNpeVF6ZEpMWXFneGVjSVFGOWpTaExDbF9tR3cyZ1RFWHBCSWpUSjVfcVRSd0w5Z09CYWx0LUx3S09JS2w2MkpFblM4cWpCQlN4SjJkcmF3ZlVsYXNkQ2luUXhuWlpJRUtPM3NtSU1iUkIyLWU5UFZZZ05KNzFCb2F3eGFvZA?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 105, "total_relevant": 66, "sentiment_summary": {"positive": 19, "negative": 1, "neutral": 46, "score": 57, "total": 66, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 23.45, "count": 42}, {"event": "earnings", "label": "Earnings", "weight": 4.81, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 2.83, "latest_week": "2026-07-17", "one_week_move": -4.9, "four_week_move": -0.4, "twelve_week_move": -4.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.58618, "market_dynamics_buy_signal": false, "relative_strength": -2.414322, "fair_value_gap": -60.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.6827, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.9% over one week, -0.4% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 9}, {"label": "TradingView", "count": 8}, {"label": "simplywall.st", "count": 5}, {"label": "www.marketscreener.com", "count": 3}, {"label": "Insider Monkey", "count": 3}, {"label": "Finviz", "count": 2}, {"label": "TradingKey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 57}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 42}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 5}, {"label": "Guidance", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "57", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.9% over one week, -0.4% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of \"Moderate Buy\" by Analysts"}], "updated_at": "2026-07-23T01:02:44.666522+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}